title: Perinatal hepatitis B prevention program in Shandong Province, China. Evaluation and progress.
abstract: Post-exposure prophylaxis with hepatitis B vaccine (HepB) alone is highly effective in preventing perinatal hepatitis B virus (HBV) transmission and the World Health Organization recommends administering HepB to all infants within 24 h after delivery. Maternal screening for HBsAg and administration of hepatitis B immune globulin (HBIG) in addition to HepB for infants born to HBsAg-positive pregnant women can increase the effectiveness of post-exposure prophylaxis for perinatal HBV transmission. In Shangdong Province, China which has a high prevalence of chronic HBV infection, HepB birth dose and HBIG were integrated into the routine childhood immunization program in 2002 and July 2011 respectively. We assessed progress toward implementation of these measures. Hospital-based reporting demonstrated an increase in maternal screening from 70.7% to 96.9% from 2004-2012; HepB birth dose coverage (within 24 h) remained high (96.3-97.1%) during this period. For infants with known HBsAg-positive mothers, the coverage of HBIG increased from 85.0% (before July 2011) to 92.1% (after July 2011). However, HBIG coverage in western areas of Shandong Province remained at 81.1% among infants with known HBsAg-positive mothers. Preterm/low-birth-weight and illness after birth were the most commonly reported reasons for delay in the first dose of HepB to >24 h of birth. Additional education on the safety and immune protection from HepB and HBIG might help to correct delays in administering the HepB birth dose and low HBIG coverage in the western areas of the Shandong Province.
authors.affiliation: a Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention; Shandong Center for Disease Control and Prevention ; Jinan , China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Stephen
authors.initials: S
authors.lastname: Ko
authors.forename: Jingjing
authors.initials: J
authors.lastname: Lv
authors.forename: Feng
authors.initials: F
authors.lastname: Ji
authors.forename: Bingyu
authors.initials: B
authors.lastname: Yan
authors.forename: Fujie
authors.initials: F
authors.lastname: Xu
authors.forename: Aiqiang
authors.initials: A
authors.lastname: Xu
mesh_terms: D002681:China; D005260:Female; D006302:Health Services Research; D006509:Hepatitis B / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000008:administration & dosage* / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000276:immunology; D007231:Infant, Newborn; D008403:Mass Screening; D018743:Perinatal Care / Q000379:methods*; D011247:Pregnancy
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D016756:Immunoglobulins, Intravenous
keywords: CDC, Centers for Disease Control and Prevention; China; HBIG, hepatitis B immune globulin; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HepB, hepatitis B vaccine; Hepatitis B; PEP, Postexposure prophylaxis; perinatal transmission; prevention